Literature DB >> 24668752

The alternative complement pathway regulates pathological angiogenesis in the retina.

J Harry Sweigard1, Ryoji Yanai1, Philipp Gaissert1, Magali Saint-Geniez2, Keiko Kataoka1, Aristomenis Thanos1, Gregory L Stahl3, John D Lambris4, Kip M Connor5.   

Abstract

A defining feature in proliferative retinopathies is the formation of pathological neovessels. In these diseases, the balance between neovessel formation and regression determines blindness, making the modulation of neovessel growth highly desirable. The role of the immune system in these retinopathies is of increasing interest, but it is not completely understood. We investigated the role of the alternative complement pathway during the formation and resolution of aberrant neovascularization. We used alternative complement pathway-deficient (Fb(-/-)) mice and age- and strain-matched control mice to assess neovessel development and regression in an oxygen-induced retinopathy (OIR) mouse model. In the control mice, we found increased transcription of Fb after OIR treatment. In the Fb(-/-) mice, we prepared retinal flatmounts and identified an increased number of neovessels, peaking at postnatal day 17 (P17; P=0.001). Subjecting human umbilical vein endothelial cells (HUVECs) to low oxygen, mimicking a characteristic of neovessels, decreased the expression of the complement inhibitor Cd55. Finally, using laser capture microdissection (LCM) to isolate the neovessels after OIR, we found decreased expression of Cd55 (P=0.005). Together, our data implicate the alternative complement pathway in facilitating neovessel clearance by down-regulating the complement inhibitor Cd55 specifically on neovessels, allowing for their targeted removal while leaving the established vasculature intact.-Sweigard, J. H., Yanai, R., Gaissert, P., Saint-Geniez, M., Kataoka, K., Thanos, A., Stahl, G. L., Lambris, J. D., Connor, K. M. The alternative complement pathway regulates pathological angiogenesis in the retina. © FASEB.

Entities:  

Keywords:  Cd55; factor b; innate immune system; neovascularization; oxygen-induced retinopathy

Mesh:

Substances:

Year:  2014        PMID: 24668752      PMCID: PMC4062823          DOI: 10.1096/fj.14-251041

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  50 in total

Review 1.  Complement. Second of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

Review 2.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 3.  Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1.

Authors:  D Hourcade; M K Liszewski; M Krych-Goldberg; J P Atkinson
Journal:  Immunopharmacology       Date:  2000-08

4.  Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.

Authors:  K K Hamilton; Z Ji; S Rollins; B H Stewart; P J Sims
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

5.  Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.

Authors:  H Ozaki; M S Seo; K Ozaki; H Yamada; E Yamada; N Okamoto; F Hofmann; J M Wood; P A Campochiaro
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Membrane cofactor protein (MCP; CD46) expression in transgenic mice.

Authors:  C Kemper; M Leung; C B Stephensen; C A Pinkert; M K Liszewski; R Cattaneo; J P Atkinson
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  The membrane attack complex of complement induces caspase activation and apoptosis.

Authors:  Alma J Nauta; Mohamed R Daha; Odette Tijsma; Bob van de Water; Francesco Tedesco; Anja Roos
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

8.  Decay-accelerating factor in the cardiomyocytes of normal individuals and patients with myocardial infarction.

Authors:  A Zimmermann; H Gerber; V Nussenzweig; H Isliker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

9.  HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.

Authors:  Masanobu Morita; Osamu Ohneda; Toshiharu Yamashita; Satoru Takahashi; Norio Suzuki; Osamu Nakajima; Shimako Kawauchi; Masatsugu Ema; Shigeki Shibahara; Tetsuo Udono; Koji Tomita; Makoto Tamai; Kazuhiro Sogawa; Masayuki Yamamoto; Yoshiaki Fujii-Kuriyama
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

10.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more
  20 in total

Review 1.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 2.  New insight into the role of the complement in the most common types of retinopathy-current literature review.

Authors:  Martyna Chrzanowska; Anna Modrzejewska; Monika Modrzejewska
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

Review 3.  Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye.

Authors:  Abdoulaye Sene; David Chin-Yee; Rajendra S Apte
Journal:  Trends Mol Med       Date:  2014-11-01       Impact factor: 11.951

4.  Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis.

Authors:  Caleb Sutherland; Yu Wang; Robert V Brown; Julie Foley; Beth Mahler; Kyathanahalli S Janardhan; Ramesh C Kovi; Anton M Jetten
Journal:  J Vis Exp       Date:  2018-06-03       Impact factor: 1.355

5.  Activated complement classical pathway in a murine model of oxygen-induced retinopathy.

Authors:  Xue-Ying Tao; Shi-Jie Zheng; Bo Lei
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

6.  Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium.

Authors:  I Kourtzelis; A Ferreira; I Mitroulis; D Ricklin; S R Bornstein; C Waskow; J D Lambris; T Chavakis
Journal:  Horm Metab Res       Date:  2014-10-28       Impact factor: 2.936

7.  Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury.

Authors:  J Harry Sweigard; Hidetaka Matsumoto; Kaylee E Smith; Leo A Kim; Eleftherios I Paschalis; Yoko Okonuki; Alexandra Castillejos; Keiko Kataoka; Eiichi Hasegawa; Ryoji Yanai; Deeba Husain; John D Lambris; Demetrios Vavvas; Joan W Miller; Kip M Connor
Journal:  Sci Transl Med       Date:  2015-07-22       Impact factor: 17.956

Review 8.  Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH.

Authors:  Hany Ibrahim Kenawy; Ismet Boral; Alan Bevington
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

9.  The alternative complement pathway aids in vascular regression during the early stages of a murine model of proliferative retinopathy.

Authors:  Clifford Kim; Kaylee E Smith; Alexandra Castillejos; Daniel Diaz-Aguilar; Magali Saint-Geniez; Kip M Connor
Journal:  FASEB J       Date:  2015-11-30       Impact factor: 5.191

10.  Revisiting the mouse model of oxygen-induced retinopathy.

Authors:  Clifford B Kim; Patricia A D'Amore; Kip M Connor
Journal:  Eye Brain       Date:  2016-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.